No. The US has improved some technical and logistical elements since COVID-19 but remains underprepared for another severe pandemic or major health crisis due to persistent structural, bureaucratic, supply-chain, trust, and capacity failures.
Documented Strengths and Incremental Fixes
•Biotech and countermeasures speed: mRNA/platform technologies (proven in Operation Warp Speed) and private-sector R&D capacity allow faster vaccine/therapeutic development than in 2020. Genomic sequencing, wastewater surveillance, and some diagnostic surge capacity have expanded. The Strategic National Stockpile has been partially rebuilt for PPE, antivirals, and certain vaccines.
•Federal initiatives: Post-COVID reviews led to efforts like HHS’s Project NextGen, BARDA investments, and attempts at CDC data modernization. The US still ranks relatively high on paper in indices that emphasize funding, labs, and plans (e.g., earlier Global Health Security Index results), and it retains unmatched wealth and manufacturing potential when aligned.
•State/local variation: Some states and health systems improved hospital surge protocols, telehealth, and stockpiles based on 2020–2022 experience.
These are real but narrow. They address “can we invent a countermeasure” more than “can we detect early, distribute equitably without chaos, maintain care for everything else, and sustain public compliance.”
Core Weaknesses That Have Not Been Fixed
•Supply chains and manufacturing: Heavy dependence on China and other foreign sources for APIs, PPE, reagents, and antibiotics persists. Domestic surge manufacturing for simple goods remains fragile; just-in-time inventory culture was not fundamentally reversed.
•Public health bureaucracy and incentives: CDC, FDA, and HHS demonstrated slow testing rollout, shifting/overconfident guidance, and data opacity in 2020. Reforms have been incremental and contested; core problems of risk aversion, political capture, and poor real-time surveillance integration remain. Gain-of-function and lab-safety oversight debates continue without consensus resolution. Early-warning systems still struggle with international opacity (China, WHO politics).
•Healthcare capacity and workforce: Hospitals run near capacity in normal times. Nurse/physician shortages, rural closures, and burnout were worsened by COVID policies and have not recovered fully. Non-pandemic care (cancer screens, elective procedures, mental health, chronic disease) collapses under surge—exactly as seen before. Excess deaths analyses and ICU data from 2020–2022 exposed this fragility.
•Trust and social cohesion: Confidence in CDC, FDA, NIH, and “the science” institutions fell sharply after contradictory messaging, school closures, mandate overreach, suppression of lab-leak and early-treatment discussion, and economic tradeoffs that were downplayed. Uptake of future countermeasures will be lower; compliance with non-pharmaceutical interventions will be contested. Polarization turns every outbreak into a culture-war proxy.
•Governance and legal mess: Emergency powers, liability, interstate coordination, and vaccine/drug EUAs sit on shaky, politicized foundations. Fiscal response capacity exists but produces inflation, debt, and misallocation (as in 2020–2021). Federalism helps experimentation yet produces patchwork failure under stress.
•Broader resilience gaps: Obesity, metabolic disease, vitamin D deficiency, and sedentary populations amplify severity for respiratory viruses. Opioid and mental-health crises already strain the same systems. Antimicrobial resistance and blood/supply shortages are chronic under-addressed risks. Border and migration health screening remains inconsistent.
Independent reviews (GAO, congressional after-actions, academic post-mortems) repeatedly flag these same issues: stockpiles deplete, plans gather dust, exercises are theatrical, and lessons from H1N1, Ebola, Zika, and COVID are only partially absorbed. Funding is lumpy—spiking after scares then fading—which prevents sustained manufacturing base and workforce pipelines.
What “Prepared” Would Actually Require
Rapid, honest detection + transparent risk communication; resilient domestic production of basics; hospitals with real slack and cross-trained staff; regulatory pathways that do not default to multi-year delays; protected civil liberties calibrated to actual lethality/transmission; and a population healthy enough that a novel pathogen does not produce outsized mortality. The US is stronger on the invention side than the execution and trust sides. A high-severity event (novel influenza, engineered pathogen, or something with higher IFR than COVID) would again produce shortages, delayed response, excess non-COVID deaths, economic damage, and bitter political fighting.
Comparisons: Countries with tighter supply control, higher baseline trust, or less obesity sometimes managed containment or mortality better in 2020, but no large, open, high-income democracy was fully ready. Pretending the US is “ready” because of money or mRNA is cargo-cult preparedness. For primary sources, see GAO pandemic reports, CDC/HHS after-action summaries, Strategic National Stockpile audits, and excess mortality studies.